Karolina Bednarska

Karolina Bednarska

Auto-generated profile, based on publicly available information

Karolina Bednarska

Blood Cancer Research Group, Mater Research, Translational Research Institute University of Queensland Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in Blood
Verified
Journal Article
Closed access
TKTakumi Kobayashi
Takumi Kobayashi
PLPui Yeng Lam
Pui Yeng Lam
HJHui Jiang
Hui Jiang
KBKarolina Bednarska
Karolina Bednarska
RGRenee Gloury
Renee Gloury
SMStephen R. Mattarollo
Stephen R. Mattarollo
Natural killer (NK) cells play critical roles in protection against hematological malignancies but can acquire a dysfunctional state, which limits antitumor immunity. However, the underlying reasons for this impaired NK cell function remain to be uncovered. We found that NK cells in aggressive B-cell lymphoma underwent substantial transcriptional reprogramming associated with increased lipid metabolism, including elevated expression of the transcriptional regulator peroxisome activator receptor-γ (PPAR-γ). Exposure to fatty acids in the lymphoma environment potently suppressed NK cell effector response and cellular metabolism. NK cells from both diffuse large B-cell lymphoma patients and Eµ-myc B-cell lymphoma-bearing mice displayed reduced interferon-γ (IFN-γ) production. Activation of PPAR-γ partially restored mitochondrial membrane potential and IFN-γ production. Overall, our data indicate that increased lipid metabolism, while impairing their function, is a functional adaptation of NK cells to the fatty-acid rich lymphoma environment.

4 May 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SLSoi C. Law
Soi C. Law
THThanh Hoang
Thanh Hoang
KOKacey O’rOurke
Kacey O’rOurke
JTJoshua W.D. Tobin
Joshua W.D. Tobin
JGJay Gunawardana
Jay Gunawardana
MGMaher Gandhi
Maher Gandhi
Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post‐transplantation lymphoproliferative disorder ‘PTLD’) is a highly aggressive non‐Hodgkin lymphoma. It is typically treated with high‐dose methotrexate‐based regimens. Outcomes are dismal and clinical trials are lacking. It is almost always Epstein‐Barr virus (EBV)‐associated. Two patients (CA1‐2) presented with EBV‐associated PCNSL after renal transplant. CA1 was on hemodialysis, and had prior disseminated cryptococcus and pseudomonas bronchiectasis, precluding treatment with methotrexate. CA2 was refractory to methotrexate. Both were treated off‐label with the first‐generation Bruton’s tyrosine kinase inhibitor ibrutinib for 12 months. Cerebrospinal fluid penetration at therapeutic levels was confirmed in CA1 despite hemodialysis. Both patients entered remission by two months. Sequencing confirmed absence of genetic aberrations in HLA‐class I/II and antigen‐presentation/processing genes, indicating retention of the ability to present EBV‐antigens. Between weeks 10‐13, they received 3rd party EBV‐specific T cells for consolidation with no side effects. They remain in remission ≥34 months since therapy began. The strength of these findings led to an ongoing phase I study (ACTRN12618001541291).

17 August 2024 in American Journal of Hematology
Verified
Journal Article
Open access
JGJay Gunawardana
Jay Gunawardana
SLSoi C. Law
Soi C. Law
MSMuhammed B Sabdia
Muhammed B Sabdia
EFEanna Fennell
Eanna Fennell
AHAoife Hennessy
Aoife Hennessy
MGMaher Gandhi
Maher Gandhi
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2‐fold enrichment in programmed cell death‐1 (PD‐1) and T‐cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra‐tumoral protein expression of PD‐1+ (and/or TIGIT+) CD4+ T‐cells and PD‐1+CD8+ T‐cells in NLPHL compared to cHL. This included T‐cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed–Sternberg (HRS) cells. In NLPHL, intra‐tumoral PD‐1+CD4+ T‐cells frequently expressed TCF‐1, a marker of heightened T‐cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD‐1+TIGIT+ in TH1, TH2, and regulatory CD4+ T‐cells in NLPHL versus cHL. Circulating PD‐1+CD4+ had high levels of TCF‐1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD‐1+CD4+ and TIGIT+PD‐1+CD8+ T‐cells in the blood were also present in the TME, indicating that immune‐checkpoint expressing T‐cells circulated between intra‐tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.

14 October 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
JGJay Gunawardana
Jay Gunawardana
JLJustina N. Lee
Justina N. Lee
KBKarolina Bednarska
Karolina Bednarska
VMValentine Murigneux
Valentine Murigneux
LLLilia Merida de Long
Lilia Merida de Long
MGMaher Gandhi
Maher Gandhi
Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma. Twenty to twenty‐five percent of FL patients have progression of disease within 24 months. These patients may benefit from immunotherapy if intact antigen presentation is present. Molecular mechanisms impairing major histocompatibility complex class‐I (MHC‐I) in FL remain undefined. Here, by sequencing of 172 FL tumours, we found the MHC‐I transactivator NLRC5 was the most frequent gene abnormality in the MHC‐I pathway. Pyrosequencing showed that epigenetic silencing of the NLRC5 promoter occurred in 30% of cases and was mutually exclusive to copy number loss (CNL) in NLRC5 (∼6% of cases). Hypermethylation and CNLs (“NLRC5 aberrant”) had reduced NLRC5 gene expression compared to wild‐type (WT) cases. By NanoString, there was reduced gene expression of the MHC‐I pathway in aberrant tissues, including immunoproteasome components (PSMB8 and PSMB9), peptide transporters of antigen processing (TAP1), and MHC‐I (HLA‐A), compared to WT. By immunofluorescent microscopy, fewer NLRC5 protein‐expressing malignant B‐cells were observed in NLRC5 aberrant tissue sections compared to NLRC5 WT (P < .01). Consistent with a pivotal role in the activation of CD8+ T‐cells, both CD8 and CD137 strongly correlated with NLRC5 expression (both r > 0.7; P < .0001). Further studies are required to determine whether patients with aberrant NLRC5 have a diminished response to immunotherapy.


1 January 2016 in Family Medicine & Primary Care Review
Verified
Journal Article
Open access
EHEwelina Hallmann
Ewelina Hallmann
RRRabczenko Rabczenko
Rabczenko Rabczenko
KBKarolina Bednarska
Karolina Bednarska
KKKatarzyna Kondratiuk
Katarzyna Kondratiuk
LBLidia Bernadeta Brydak
Lidia Bernadeta Brydak
Background . Influenza remains the cause of many seasonal infections, leading even to death, in all age groups, for all patient health states, under all health policies, and in all latitudes. Influenza infection needs to be thought of not only in terms of the loss of health and the exacerbation...